FibroGen, Inc.

FGEN
Delayed Nasdaq - 12/13 10:00:00 pm
46.69USD
-1.99%
Prev.47.6400
Open47.5500
High48.4900
Low46.5400
Volume652 570
Financials
Sales 2019 299 M
EBIT 2019 -22,4 M
Net income 2019 -19,5 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -208x
P/E ratio 2020 -257x
Capi. / Sales2019 13,6x
Capi. / Sales2020 12,9x
Capitalization 4 074 M
Company
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia,...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2020-02-26 Earnings Release
Trading Rating :
Investor Rating :
Latest news
12/03FIBROGEN : Announces Roxadustat Inclusion in China's National Reimbursement Drug List
AQ
12/02FIBROGEN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
12/02FibroGen Announces Roxadustat Inclusion in China's National Reimbursement Drug List
GL
11/14FIBROGEN ALERT : Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
BU
11/13GLANCY PRONGAY & MURRAY LLP : Announces Investigation on Behalf of FibroGen, Inc. Investors
BU
11/13Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors
BU
11/12FIBROGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)
AQ
11/12FIBROGEN INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishNeutralNeutral
Resistance48,548,559,9
Spread/Res.-3,6%-3,6%-22%
Spread/Supp.12%35%31%
Support41,634,635,6